Stoke Therapeutics Financials - Benzinga

Stoke Therapeutics Inc

STOKNASDAQ

Trade with Public

Trade with Public

$32.71

0.782.44%

At close: Aug 7, 5:00 PM EST

$32.80

0.090.28%

After Hours: Aug 7, 4:09 PM EST

Earnings: Q2 2026 Earnings were released on Mon Aug 3rd, after the market close

Conference Call: The most recent conference call started at 4:30 PM, 6 days ago

Click to view the webcast

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Stoke Therapeutics Financials

Stoke Therapeutics (STOK) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results

Stoke Therapeutics (STOK) reported mixed Q2 results with losses of 93 cents per share and sales of $9.325 million. Analysts have mixed opinions.

Avi Kapoor

PRO
Stoke Therapeutics Q2 EPS $(0.93) Misses $(0.80) Estimate, Sales $9.325M Beat $6.044M Estimate

Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.80) by 16.25 percent. This is a 132.5 percent decrease over losses of $(0.40) per share

Benzinga Newsdesk

PRO
Stoke Therapeutics Q1 EPS $(0.79) Beats $(0.84) Estimate, Sales $6.229M Beat $5.880M Estimate.

Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0.84) by 5.95 percent. This is a 141.58 percent decrease over earnings of $1.90 per share

Benzinga Newsdesk

PRO
Stoke Therapeutics Q3 EPS $(0.65) Misses $(0.59) Estimate, Sales $10.632M Beat $5.511M Estimate

Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.59) by 10.36 percent. This is a 38.3 percent decrease over losses of $(0.47) per share

Benzinga Newsdesk

Earnings Scheduled For November 4, 2025

Benzinga Insights

Examining the Future: Stoke Therapeutics's Earnings Outlook

Benzinga Insights